Certolizumab Pegol-induced Palmoplantar Pustulosis: A Case Report and Review of the Literature

[1]  M. Akiyama,et al.  Certolizumab pegol, a pegylated anti‐TNF‐α antagonist, caused de novo‐onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis , 2017, The Journal of dermatology.

[2]  M. Tollefson,et al.  Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti–Tumor Necrosis Factor Alpha Agents , 2017, Pediatric dermatology.

[3]  E. Linos,et al.  Tumor necrosis factor‐&agr; inhibitor‐induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience , 2017, Journal of the American Academy of Dermatology.

[4]  R. Fischer,et al.  Certolizumab-induced guttate psoriasiform dermatitis. , 2017, Dermatology online journal.

[5]  A. Schoepfer,et al.  Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels , 2016, Scandinavian journal of gastroenterology.

[6]  H. Yamanaka.  TNF as a Target of Inflammation in Rheumatoid Arthritis. , 2015, Endocrine, metabolic & immune disorders drug targets.

[7]  M. Miteva,et al.  A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect. , 2012, The Journal of clinical and aesthetic dermatology.

[8]  K. Choate,et al.  Psoriatic skin lesions induced by certolizumab pegol. , 2010, Archives of dermatology.

[9]  M. Cottone,et al.  Severe Cutaneous Psoriasis After Certolizumab Pegol Treatment: Report of a Case , 2009, The American Journal of Gastroenterology.

[10]  J. S. Henning,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.